
When most people picture drug development, they tend to imagine a scientist in a lab coat mixing chemicals until something kills cancer cells. And honestly, that isn’t totally wrong. I do wear a lab coat and while I’m not the one doing the actual chemical mixing, someone else in a lab coat is. But that picture skips over a huge chunk of the story because a ton of the work happens before a single drug molecule is even made. After all, it’s pretty hard to hit a target if you don’t have a target to aim for. So, let’s take a step back and talk about how we even find a target in the first place.
When it comes to finding a target, we’re generally looking for genes or proteins that are different in the tumour compared to normal healthy tissue. These changes might be mutated genes or overactive proteins. These proteins can also show up in much larger amounts than usual. As a tumour grows, its cells pick up loads of genetic changes along the way. So, by comparing a tumour to healthy cells, we can usually spot plenty of differences. The catch is that there are often thousands of differences, and many of them aren’t actually doing much. To make sense of them, scientists sort these changes into two groups: “drivers” and “passengers.” If you think of a tumour as a car, a driver mutation is, well, the driver. It has its foot on the gas and is steering the cancer to grow and survive. Passenger mutations are just sitting in the back seat, along for the ride. If you kick a passenger out, the car will keep going but if you take away the driver, the car will (hopefully) roll to a stop. So, the hard part isn’t finding the differences in cancer cells, it’s figuring out which ones are behind the proverbial wheel.
Instead of just asking “is this feature there?”, we ask, “if we take it away, does the cancer struggle?” This is a process called target validation, and it’s an essential step before we can even start thinking about developing a drug. Most of the time, target validation begins with early experiments performed in vitro, which is Latin for “in glass,” and a fancy way of saying cells grown in a dish. We can use genetic tools to turn the expression of a target gene down or off completely. Then, we watch what happens. Do the cancer cells grow more slowly or die? Are they more sensitive to certain therapies? How does their behaviour change? While in vitro experiments can give us an idea of whether or not a target might be a driver, they can’t really tell us the full story. Living in a dish is a very cozy place compared to a real tumour. As my friends and family know, I spend a lot of time just taking care of my cells to keep them happy and growing nicely. So, promising targets are then tested in vivo (“within the living”), usually in mice. Suddenly, our cancer cells have to deal with blood vessels, immune cells, neighbouring tissues and everything else that comes with living inside a whole body. Sometimes a target that looked promising in a dish turns out to barely matter in a mouse, and back to the drawing board we go.
If a target has survived all of this, we can finally call it “validated.” But a validated target isn’t a drug yet. Remember RAS from my last blog post? Scientists have known it’s a major cancer driver since the 1980s, yet it took decades to design a drug that could actually hit it. As it turns out, knowing what to aim at and being able to hit it are two very different problems. So, on our next stop, we’ll explore what makes a target “druggable” and how scientists find the very first molecules that might one day become a medication.